4Special
issues -- preoperative
medication differences between adult and pediatric patients
-
4Overview:
-
Review of the general
rationale for the use of sedative-hypnotic drugs:
-
Reduce anxiety
-
Produce sedation/amnesia
-
Promote soon as anesthesia
induction by inhalational methods
-
Use of preoperative agents in
pediatric patients may not be completely successful in as high
as 20% of cases.
-
After about six months-one-year
of age, administration of a sedative-hypnotic agent may be
beneficial to the patient.
-
4Sedative-hypnotics
-
Midazolam (Versed) [may be
given intramuscularly, 0.2 mg/kg, if necessary] is given by
the preferred oral route following mixing of 0.5-0.75
mg/kg of the drug with a flavored agent such as syrup, cola,
or fruit juice to mask the bitter-tasting drug.
-
Oral ketamine (Ketalar): 20-30
minutes before induction, oral ketamine (Ketalar) at a dosage
of 5-10 mg may be given.
-
Methohexital (Brevital): This
agent may be given just prior to surgery at a dosage of 20-30
mg/kg using the rectal route of administration; however,
intramuscular administration may also be employed.
-
Other Routes of Administration:
-
4Anticholinergic drugs:
-
Overview:
-
The use of anticholinergic
agents is especially important because children have
easily-induced vagal reflexes that may induce bradycardia.
-
Bradycardia may be induced
through the vagal reflex by the surgical activity itself,
airway manipulation, or by anesthetic drugs such as
halothane (Fluothane) or succinylcholine (Anectine)
-
Most pediatric patients are
given an anticholinergic agent, typically atropine, just after
anesthesia induction and placement of the intravenous
catheter. This procedure is dependent on an absence of
contraindications to atropine.
-
Intramuscular injection as
an option is possible and if implemented, the injection
would occur just after the child loses consciousness
during induction
-
An alternative to atropine
would be glycopyrrolate (Robinul); however, scopolamine
might be used because of its ability to produce sedation,
amnesia, and to reduce airway secretion.
-
Special concerns:
-
Anticholinergic drugs
decrease effective temperature regulation by preventing
sympathetic cholinergic mediation of sweating {sweat
glands are innervated by sympathetic cholinergic fibers
that depend on available muscarinic receptors for
activity; anticholinergic drugs are competitive
antagonists at these receptor sites and therefore
interfere with sweat gland activity}
-
Because anticholinergic
drugs are likely to cause a thickening of secretion,
one might select not to use anticholinergic drugs if
inspissation of secretion is undesirable {for example in a
cystic fibrosis patient}
-
A patient with trisomy 21
(Down syndrome) may be more sensitive to cardiovascular
effects of atropine and more likely to exhibit mydriasis.
References:
-
1Preoperative Medication in
Basis of Anesthesia, 4th Edition, Stoelting, R.K. and Miller, R.,
p 119- 130, 2000)
-
Hobbs, W.R, Rall, T.W., and Verdoorn, T.A., Hypnotics and Sedatives;
Ethanol In, Goodman and Gillman's The Pharmacologial
Basis of Therapeutics, pp. 364-367 (Hardman, J.G, Limbird, L.E, Molinoff, P.B.,
Ruddon, R.W, and Gilman, A.G.,eds) TheMcGraw-Hill Companies, Inc.,
1996.
-
3Sno E. White The Preoperative
Visit and Premedication in Clinical Anesthesia Practice pp.
576-583 (Robert Kirby & Nikolaus Gravenstein, eds) W.B.
Saunders Co., Philadelphia, 1994
-
4John R. Moyers
and Carla M. Vincent Preoperative Medication in Clinical Anethesia,
4th edition, 551-565, (Paul G. Barash, Bruce. F. Cullen, Robert K. Stoelting,
eds) Lippincott Williams & Wilkins, Philadelphia, PA, 2001
-
5Gertler, R.,
Brown, H. C, Mitchell, D.H and Silvius, E.N Dexmedetomidine (Precedex):
a novel sedative-analgesic agent, BUMC Proceedings 2001; 14:13-21
(http://www.baylorhealth.com/proceedings/14_1/14_1_gertler.htm)
|